Fulcrum Therapeutics, Inc. – NASDAQ:FULC

Fulcrum Therapeutics stock price today

$6.41
+1.62
+33.82%
Financial Health
0
1
2
3
4
5
6
7
8
9

Fulcrum Therapeutics stock price monthly change

-40.20%
month

Fulcrum Therapeutics stock price quarterly change

-40.20%
quarter

Fulcrum Therapeutics stock price yearly change

-29.04%
year

Fulcrum Therapeutics key metrics

Market Cap
236.79M
Enterprise value
90.80M
P/E
-1.19
EV/Sales
14.31
EV/EBITDA
-0.84
Price/Sales
17.73
Price/Book
0.56
PEG ratio
0.18
EPS
-1.6
Revenue
N/A
EBITDA
-110.47M
Income
-99.42M
Revenue Q/Q
-100%
Revenue Y/Y
-37.94%
Profit margin
-1732.43%
Oper. margin
-1767.52%
Gross margin
0%
EBIT margin
-1767.52%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Fulcrum Therapeutics stock price history

Fulcrum Therapeutics stock forecast

Fulcrum Therapeutics financial statements

Fulcrum Therapeutics, Inc. (NASDAQ:FULC): Profit margin
Jun 2023 880K -23.78M -2702.61%
Sep 2023 759K -24.01M -3164.3%
Dec 2023 871K -24.75M -2842.25%
Mar 2024 0 -26.87M
Fulcrum Therapeutics, Inc. (NASDAQ:FULC): Analyst Estimates
Mar 2024 0 -26.87M
Sep 2025 786.43K -30.93M -3933.64%
Oct 2025 0 -39.66M
Dec 2025 0 -37.19M
  • Analysts Price target

  • Financials & Ratios estimates

Fulcrum Therapeutics, Inc. (NASDAQ:FULC): Debt to assets
Jun 2023 300332000 24.90M 8.29%
Sep 2023 278879000 23.41M 8.4%
Dec 2023 257694000 22.50M 8.73%
Mar 2024 232588000 18.99M 8.17%
Fulcrum Therapeutics, Inc. (NASDAQ:FULC): Cash Flow
Jun 2023 -20.78M 19.87M 142K
Sep 2023 -22.90M 19.02M 117.83M
Dec 2023 -23.15M 18.35M 287K
Mar 2024 -25.28M 38.12M 1.65M

Fulcrum Therapeutics alternative data

Fulcrum Therapeutics, Inc. (NASDAQ:FULC): Employee count
Aug 2023 89
Sep 2023 89
Oct 2023 89
Nov 2023 89
Dec 2023 89
Jan 2024 89
Feb 2024 89
Mar 2024 76
Apr 2024 76
May 2024 76
Jun 2024 76
Jul 2024 76

Fulcrum Therapeutics other data

100.00% +1.90%
of FULC is owned by hedge funds
50.76M +10.89M
shares is hold by hedge funds

Fulcrum Therapeutics, Inc. (NASDAQ:FULC): Insider trades (number of shares)
Period Buy Sel
Mar 2024 43360 4884
May 2024 0 236
Transaction Date Insider Security Shares Price per share Total value Source
Sale
TOURANGEAU GREG officer: Principal Accounting O..
Common Stock 236 $7.76 $1,831
Sale
TOURANGEAU GREG officer: Vice President, Finance
Common Stock 4,884 $11.72 $57,221
Purchase
SAPIR ALEX director, officer: See Remarks
Common Stock 43,360 $11.35 $492,049
Sale
TOURANGEAU GREG officer: Principal Accounting O..
Common Stock 210 $3.31 $695
Purchase
RA CAPITAL MANAGEMENT, L.P. 10 percent owner
Common Stock 1,923,076 $13 $24,999,988
Sale
GOULD ROBERT J director, officer: Interim Pres..
Common Stock 6,766 $15 $101,490
Purchase
RA CAPITAL MANAGEMENT, L.P. 10 percent owner
Common Stock 58,369 $7.8 $455,103
Purchase
RA CAPITAL MANAGEMENT, L.P. 10 percent owner
Common Stock 122,334 $7.03 $859,763
Purchase
RA CAPITAL MANAGEMENT, L.P. 10 percent owner
Common Stock 4,089 $5.99 $24,509
Purchase
RA CAPITAL MANAGEMENT, L.P. 10 percent owner
Common Stock 98,787 $5.9 $582,843
Patent
Application
Filling date: 18 Feb 2021 Issue date: 26 May 2022
Application
Filling date: 12 Nov 2021 Issue date: 5 May 2022
Application
Filling date: 20 Nov 2019 Issue date: 20 Jan 2022
Grant
Filling date: 24 Apr 2020 Issue date: 13 Apr 2021
Application
Filling date: 21 Jan 2020 Issue date: 10 Dec 2020
Application
Filling date: 24 Apr 2020 Issue date: 19 Nov 2020
Application
Filling date: 5 Oct 2018 Issue date: 22 Oct 2020
Grant
Filling date: 19 Nov 2018 Issue date: 21 Jan 2020
Thursday, 28 November 2024
zacks.com
Tuesday, 26 November 2024
globenewswire.com
Wednesday, 13 November 2024
seekingalpha.com
Tuesday, 12 November 2024
globenewswire.com
zacks.com
Wednesday, 6 November 2024
globenewswire.com
Friday, 25 October 2024
zacks.com
Tuesday, 15 October 2024
accesswire.com
Monday, 14 October 2024
accesswire.com
Friday, 11 October 2024
globenewswire.com
accesswire.com
Thursday, 10 October 2024
accesswire.com
Wednesday, 9 October 2024
zacks.com
accesswire.com
Tuesday, 8 October 2024
accesswire.com
Monday, 7 October 2024
gurufocus.com
accesswire.com
Friday, 4 October 2024
zacks.com
Wednesday, 2 October 2024
accesswire.com
Tuesday, 1 October 2024
accesswire.com
accesswire.com
Monday, 30 September 2024
accesswire.com
accesswire.com
Sunday, 29 September 2024
accesswire.com
accesswire.com
Saturday, 28 September 2024
accesswire.com
accesswire.com
Friday, 27 September 2024
accesswire.com
accesswire.com
accesswire.com
  • What's the price of Fulcrum Therapeutics stock today?

    One share of Fulcrum Therapeutics stock can currently be purchased for approximately $6.41.

  • When is Fulcrum Therapeutics's next earnings date?

    Unfortunately, Fulcrum Therapeutics's (FULC) next earnings date is currently unknown.

  • Does Fulcrum Therapeutics pay dividends?

    No, Fulcrum Therapeutics does not pay dividends.

  • How much money does Fulcrum Therapeutics make?

    Fulcrum Therapeutics has a market capitalization of 236.79M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 55.77% to 2.81M US dollars.

  • What is Fulcrum Therapeutics's stock symbol?

    Fulcrum Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "FULC".

  • What is Fulcrum Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Fulcrum Therapeutics?

    Shares of Fulcrum Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Fulcrum Therapeutics's key executives?

    Fulcrum Therapeutics's management team includes the following people:

    • Mr. Bryan E. Stuart Pres, Chief Executive Officer & Director(age: 49, pay: $598,400)
    • Mr. Curtis G. Oltmans J.D. Senior Vice President, Gen. Counsel & Corporation Sec.(age: 62, pay: $83,980)
    • Mr. Mark J. Levin Executive Chairman(age: 75, pay: $73,000)
  • How many employees does Fulcrum Therapeutics have?

    As Jul 2024, Fulcrum Therapeutics employs 76 workers.

  • When Fulcrum Therapeutics went public?

    Fulcrum Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 18 Jul 2019.

  • What is Fulcrum Therapeutics's official website?

    The official website for Fulcrum Therapeutics is fulcrumtx.com.

  • Where are Fulcrum Therapeutics's headquarters?

    Fulcrum Therapeutics is headquartered at 26 Landsdowne Street, Cambridge, MA.

  • How can i contact Fulcrum Therapeutics?

    Fulcrum Therapeutics's mailing address is 26 Landsdowne Street, Cambridge, MA and company can be reached via phone at +61 76518851.

Fulcrum Therapeutics company profile:

Fulcrum Therapeutics, Inc.

fulcrumtx.com
Exchange:

NASDAQ

Full time employees:

76

Industry:

Biotechnology

Sector:

Healthcare

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

26 Landsdowne Street
Cambridge, MA 02139

CIK: 0001680581
ISIN: US3596161097
CUSIP: 359616109